Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
It is shown that sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer and was also associated with clinical benefit rate and overall survival.
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer…
Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes
The use of IL-10 in combination with IL-2 for the in vitro expansion and potentiation of tumor-specific CTL for clinical use in the therapy of cancer is supported.
Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.
It is determined that TAMs promote spheroid formation and tumor growth at early stages of transcoelomic metastasis in an established mouse model for epithelial ovarian cancer.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Single-agent pembrolizumab showed modest activity in patients with ROC and higher PD-L1 expression was correlated with higher response.
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type‐specific therapies against this disease.
Overexpression of HER-2/neu in uterine serous papillary cancer.
It is proposed that Herceptin might be a novel and attractive therapeutic strategy in patients harboring chemotherapy-resistant, recurrent, or metastatic USPC.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
- Siming Zhao, S. Bellone, A. Santin
- BiologyProceedings of the National Academy of Sciences
- 10 October 2016
The genomes of uterine and ovarian CSs demonstrated that these different cell types derive from a common precursor cell that has many mutations typical of epithelial cancers, and expression of specific histone gene mutations in uterine carcinoma cells changed gene expression toward a mesenchymal state.
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
- N. Buza, D. Roque, A. Santin
- Medicine, BiologyArchives of Pathology & Laboratory Medicine
- 27 February 2014
There is a need to develop standardized criteria for HER2 testing in endometrial carcinoma that reflect the unique biological and pathogenetic features of these tumors and correlate with clinical response to therapy.